{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:01:34Z","timestamp":1777366894594,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Lupin Limited (Research Park)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ejphar.2017.02.043","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T17:45:21Z","timestamp":1488822321000},"page":"35-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL\/6 mice"],"prefix":"10.1016","volume":"801","author":[{"given":"Umakant Ashok","family":"Bahirat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rekha Raghuveer","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan Naresh","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar V.S.","family":"Nemmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2017.02.043_bib1","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2010.09.032","article-title":"Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase","volume":"54","author":"Ben-Shlomo","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2017.02.043_bib2","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1210\/en.2007-0966","article-title":"A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release","volume":"149","author":"Chu","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2017.02.043_bib3","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1210\/en.2006-1608","article-title":"A role for \u03b2-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release","volume":"148","author":"Chu","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2017.02.043_bib4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.21006","article-title":"Exendin-4, a glucagon-Like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice","volume":"43","author":"Ding","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2017.02.043_bib5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1055\/s-2007-1003745","article-title":"Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride responses in rats","volume":"23","author":"Ebert","year":"1991","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.ejphar.2017.02.043_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1194\/jlr.M500203-JLR200","article-title":"PPAR\u03b1 activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes","volume":"47","author":"Edvardsson","year":"2006","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejphar.2017.02.043_bib7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/en.2010-1047","article-title":"GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms","volume":"152","author":"Flock","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2017.02.043_bib8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00125-009-1611-5","article-title":"The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice","volume":"53","author":"Hsieh","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2017.02.043_bib9","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.drudis.2013.09.011","article-title":"GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119","volume":"18","author":"Kang","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2017.02.043_bib10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/clpt.2011.169","article-title":"Pharmacokinetics, pharmacodynamics, safety and tolerability of JNJ-38431055, a novel GPR119 receptor agonist, in healthy male subjects","volume":"90","author":"Katz","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2017.02.043_bib11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1463-1326.2012.01587.x","article-title":"Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes","volume":"14","author":"Katz","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejphar.2017.02.043_bib12","first-page":"1","article-title":"The TRPA1 agonist, methyl Syringate suppresses food intake and gastric emptying","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2017.02.043_bib13","unstructured":"Kim, M., Kim, T.H., Cheyong, Y., Chae, Y.A., Jung, I.H., Lee, K., Choi, S.M., Yang, J.S., Son, M., Kang, K.K., 2015. Long-term treatment of DA-1241, a novel GPR119 agonist, improved glucose control via preserved beta cell mass in a progressive diabetic mice model. In: Proceedings of the 75th American Diabetes Association. 280-LB."},{"key":"10.1016\/j.ejphar.2017.02.043_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/269569","article-title":"In vivo efficacy of HD0471953: a novel GPR119 agonist for the treatment of type 2 diabetes mellitus","volume":"2013","author":"Kim","year":"2013","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.ejphar.2017.02.043_bib15","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2337\/diacare.27.6.1496","article-title":"Lipids and lipoproteins in patients with Type 2 diabetes","volume":"27","author":"Krauss","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2017.02.043_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0046300","article-title":"A potent class of GPR40 full agonists engages the enteroInsular axis to promote glucose control in rodents","volume":"7","author":"Luo","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2017.02.043_bib17","first-page":"A9918","article-title":"Novel effects on lipids of GSK1292263, a GPR119 agonist in type 2 diabetics","volume":"126","author":"Nunez","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2017.02.043_bib18","unstructured":"Nunez, D.J., Bush, M.A., Collins, D.A., Mcmullen, S.L., Feldman, P.L., Jackson, T., Ross, S., 2011. Evaluation of GSK1292263, a novel GPR119 agonist, in Type 2 diabetes mellitus (T2DM): safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple doses. In: Proceedings of the 71st American Diabetes Association, 996-P."},{"key":"10.1016\/j.ejphar.2017.02.043_bib19","doi-asserted-by":"crossref","first-page":"G943","DOI":"10.1152\/ajpgi.00303.2004","article-title":"GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats","volume":"288","author":"Qin","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejphar.2017.02.043_bib20","first-page":"G762","article-title":"Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice","volume":"302","author":"Trevaskis","year":"2012"},{"key":"10.1016\/j.ejphar.2017.02.043_bib21","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.2337\/db14-1706","article-title":"Gut peptides are novel regulators of intestinal lipoprotein secretion: experimental and pharmacological manipulation of lipoprotein metabolism","volume":"64","author":"Xiao","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2017.02.043_bib22","first-page":"1","article-title":"GPR119: a promising target for nonalcoholic fatty liver disease","volume":"30","author":"Yang","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.ejphar.2017.02.043_bib23","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.bbrc.2010.08.141","article-title":"AS1907417, a novel GPR119 agonist, as an insulinotropic and \u03b2-cell preservative agent for the treatment of type 2 diabetes","volume":"400","author":"Yoshida","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2017.02.043_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/clp.14.59","article-title":"Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors","volume":"10","author":"Zhong","year":"2015","journal-title":"Clin. Lipidol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917301310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917301310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T16:50:43Z","timestamp":1535993443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299917301310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":24,"alternative-id":["S0014299917301310"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.02.043","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL\/6 mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.02.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}